Pharmacotherapy of sarcoma

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Miller RW, Young JL, Novakovic B. Childhood cancer. Cancer 1995;75:395-405
   PubMedGoogle Scholar
• Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-9
   PubMed Web of Science ®Google Scholar
• Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45
   PubMed Web of Science ®Google Scholar
• Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-7
   PubMed Web of Science ®Google Scholar
• Borden EC, Amato DA, Edmonson JH, et al. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 1990;66:862-7
   PubMed Web of Science ®Google Scholar
• Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987;5:840-50
   PubMed Web of Science ®Google Scholar
• Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75
   PubMed Web of Science ®Google Scholar
• Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-9
   PubMed Web of Science ®Google Scholar
• Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991;68:1221-9
   PubMed Web of Science ®Google Scholar
• O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977;39:1940-8
   PubMed Web of Science ®Google Scholar
• Nielsen OS, Dombernowsky P, Mouridsen H, et al. Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas. The Experience of the EORTC Soft Tissue and Bone Sarcoma Group. Sarcoma 2000;4:31-5
   PubMedGoogle Scholar
• Scheef W, Klein HO, Brock N, et al. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep 1979;63:501-5
   PubMedGoogle Scholar
• Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 1988;80:556-66
   PubMedGoogle Scholar
• Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000;82:291-4
   PubMed Web of Science ®Google Scholar
• Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989;7:126-31
   PubMed Web of Science ®Google Scholar
• Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 1993;31(Suppl 2):S174-9
   PubMed Web of Science ®Google Scholar
• Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies–dose-response and schedule dependence. J Clin Oncol 1997;15:2378-84
   PubMed Web of Science ®Google Scholar
• Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 2004;240:686-95; discussion 695-687
   PubMed Web of Science ®Google Scholar
• Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 2007;246:105-13
   PubMed Web of Science ®Google Scholar
• Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034-37
   PubMed Web of Science ®Google Scholar
• Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005;104:361-6
   PubMed Web of Science ®Google Scholar
• Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008;44:2433-6
   PubMed Web of Science ®Google Scholar
• Schoenfeld DA, Rosenbaum C, Horton J, et al. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 1982;50:2757-62
   PubMed Web of Science ®Google Scholar
• Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003:CD003293
   Google Scholar
• Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-31
   PubMed Web of Science ®Google Scholar
• Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007;25:2755-63
   PubMed Web of Science ®Google Scholar
• Bay JO, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006;119:706-11
   PubMed Web of Science ®Google Scholar
• Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22:1706-12
   PubMed Web of Science ®Google Scholar
• Ebeling P, Eisele L, Schuett P, et al. Docetaxel and gemcitabine in the treatment of soft tissue sarcoma: a single-center experience. Onkologie 2008;31:11-16
   PubMedGoogle Scholar
• Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev 2000:CD001419
   Google Scholar
• Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647-54
   PubMed Web of Science ®Google Scholar
• Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113:573-81
   PubMed Web of Science ®Google Scholar
• Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft tissue sarcoma. Eur J Cancer 2001;37:1096-103
   PubMed Web of Science ®Google Scholar
• Reichardt P, Lindner T, Pink D, et al. Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer 2003;39:1511-16
   PubMed Web of Science ®Google Scholar
• Drilon AD, Popat S, Bhuchar G, et al. Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer 2008;113(12):3364-71
   PubMed Web of Science ®Google Scholar
• Plaat BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18:3211-20
   PubMed Web of Science ®Google Scholar
• Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6
   PubMed Web of Science ®Google Scholar
• van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38(Suppl 5):S83-7
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80
   PubMed Web of Science ®Google Scholar
• Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38
   PubMed Web of Science ®Google Scholar
• Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-73
   PubMed Web of Science ®Google Scholar
• Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008;3:557-86
   PubMed Web of Science ®Google Scholar
• Boyar MS, Taub RN. New strategies for treating GIST when imatinib fails. Cancer Invest 2007;25:328-35
   PubMed Web of Science ®Google Scholar
• Cassier PA, Dufresne A, Arifi S, et al. Imatinib mesilate for the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother 2008;9:1211-22
   PubMed Web of Science ®Google Scholar
• Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-30
   PubMed Web of Science ®Google Scholar
• Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-20
   PubMed Web of Science ®Google Scholar
• Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71:1904-22
   PubMed Web of Science ®Google Scholar
• Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-02
   PubMed Web of Science ®Google Scholar
• Vassal G, Couanet D, Stockdale E, et al. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 2007;25:356-61
   PubMedGoogle Scholar
• Antman K, Crowley J, Balcerzak SP, et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer 1998;82:1288-95
   PubMed Web of Science ®Google Scholar
• Lager JJ, Lyden ER, Anderson JR, et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2006;24:3415-22
   PubMedGoogle Scholar
• Pommier Y, Kohlhagen G, Bailly C, et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35:13303-9
   PubMed Web of Science ®Google Scholar
• Bonfanti M, La Valle E, Fernandez Sousa Faro JM, et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 1999;14:179-86
   PubMedGoogle Scholar
• Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-84
   PubMed Web of Science ®Google Scholar
• Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30
   PubMed Web of Science ®Google Scholar
• Suit H. Regaud lecture, granada 1994. Tumors of the connective and supporting tissues. Radiother Oncol 1995;34:93-104
   PubMedGoogle Scholar
• Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008;13:320-9
   PubMed Web of Science ®Google Scholar
• Askin FB, Rosai J, Sibley RK, et al. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 1979;43:2438-51
   PubMed Web of Science ®Google Scholar
• Zucman J, Delattre O, Desmaze C, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer 1992;5:271-7
   PubMed Web of Science ®Google Scholar
• Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5
   PubMed Web of Science ®Google Scholar
• Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors–a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994;331:294-9
   PubMed Web of Science ®Google Scholar
• May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 1993;90:5752-6
   PubMed Web of Science ®Google Scholar
• Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701
   PubMed Web of Science ®Google Scholar
• Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990;8:1664-74
   PubMed Web of Science ®Google Scholar
• Hustu HO, Pinkel D, Pratt CB. Treatment of clinically localized Ewing's sarcoma with radiotherapy and combination chemotherapy. Cancer 1972;30:1522-7
   PubMed Web of Science ®Google Scholar
• Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990;8:1514-24
   PubMed Web of Science ®Google Scholar
• Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-8
   PubMed Web of Science ®Google Scholar
• Magrath I, Sandlund J, Raynor A, et al. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol 1986;18(Suppl 2):S25-8
   Google Scholar
• Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: the Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 1998;16:3628-33
   PubMed Web of Science ®Google Scholar
• Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G 99 clinical trial. Pediatr Blood Cancer 2006;47:22-9
   PubMed Web of Science ®Google Scholar
• Womer RB, West DC, Krailo MD, et al. Chemotherapy intensification by interval compression in localized Ewing sarcoma family tumors (ESFT) [abstract]. Connective Tissue Oncology Society Annual Meeting, Seattle, Washington- abstract #855; 1 Nov, 2007
   Google Scholar
• Paulussen M, Ahrens S, Craft AW, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998;16:3044-52
   PubMed Web of Science ®Google Scholar
• Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457–a report from the Children's Oncology Group. J Clin Oncol 2006;24:152-9
   PubMed Web of Science ®Google Scholar
• Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004;22:2873-6
   PubMed Web of Science ®Google Scholar
• Miser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy–a report from the Children's Oncology Group. Pediatr Blood Cancer 2007;49:894-900
   PubMed Web of Science ®Google Scholar
• Atra A, Whelan JS, Calvagna V, et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997;20:843-6
   PubMed Web of Science ®Google Scholar
• Laurence V, Pierga JY, Barthier S, et al. Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor. Am J Clin Oncol 2005;28:301-9
   PubMed Web of Science ®Google Scholar
• Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000;11:1451-62
   PubMed Web of Science ®Google Scholar
• Hawkins D, Barnett T, Bensinger W, et al. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol 2000;34:328-37
   PubMedGoogle Scholar
• Wagner LM, McAllister N, Goldsby RE, et al. Temozolamide and intravneous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132-9
   PubMed Web of Science ®Google Scholar
• Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006;47:795-800
   PubMed Web of Science ®Google Scholar
• Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-9
   PubMed Web of Science ®Google Scholar
• May WA, Lessnick SL, Braun BS, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993;13:7393-8
   PubMed Web of Science ®Google Scholar
• Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-7
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4
   PubMed Web of Science ®Google Scholar
• Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor–specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007;13:1322-30
   PubMed Web of Science ®Google Scholar
• Cortes EP, Holland JF, Wang JJ, et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974;291:998-1000
   PubMed Web of Science ®Google Scholar
• Jaffe N, Frei E 3rd, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974;291:994-7
   PubMed Web of Science ®Google Scholar
• Sutow WW, Sullivan MP, Wilbur JR, Cangir A. Study of adjuvant chemotherapy in osteogenic sarcoma. J Clin Pharmacol 1975;15:530-3
   PubMedGoogle Scholar
• Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-6
   PubMed Web of Science ®Google Scholar
• Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6
   PubMed Web of Science ®Google Scholar
• Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15
   PubMed Web of Science ®Google Scholar
• Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-7
   PubMed Web of Science ®Google Scholar
• Bacci G, Gherlinzoni F, Picci P, et al. Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. Eur J Cancer Clin Oncol 1986;22:1337-45
   PubMedGoogle Scholar
• Krailo M, Ertel I, Makley J, et al. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group. Med Pediatr Oncol 1987;15:69-77
   PubMedGoogle Scholar
• Graf N, Winkler K, Betlemovic M, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994;12:1443-51
   PubMed Web of Science ®Google Scholar
• Zelcer S, Kellick M, Wexler LH, et al. Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 2005;44:638-42
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23:2004-11
   PubMed Web of Science ®Google Scholar
• Zalupski MM, Rankin C, Ryan JR, et al. Adjuvant therapy of osteosarcoma–A Phase II trial: Southwest Oncology Group study 9139. Cancer 2004;100:818-25
   PubMedGoogle Scholar
• Voute PA, Souhami RL, Nooij M, et al. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann Oncol 1999;10:1211-8
   PubMed Web of Science ®Google Scholar
• Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 1997;33:232-7
   PubMed Web of Science ®Google Scholar
• Mackall C, Berzofsky J, Helman LJ. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin Orthop Relat Res 2000;25-31
   PubMedGoogle Scholar
• Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003;3:685-94
   PubMed Web of Science ®Google Scholar
• Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 2003;21:167-76
   PubMed Web of Science ®Google Scholar
• Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 1993;31(Suppl 2):S180-4
   PubMed Web of Science ®Google Scholar
• Samson MK, Baker LH, Benjamin RS, et al. Cis-dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: a Southwest Oncology Group Study. Cancer Treat Rep 1979;63:2027-9
   PubMedGoogle Scholar
• Budd GT, Metch B, Balcerzak SP, et al. High-dose cisplatin for metastatic soft tissue sarcoma. Cancer 1990;65:866-9
   PubMedGoogle Scholar
• Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-9
   PubMed Web of Science ®Google Scholar
• Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991;2:307-9
   PubMed Web of Science ®Google Scholar
• Bramwell V, Blackstein M, Belanger K, et al. A phase II study of docetaxel in chemotherapy-naive patients with recurrent or metastatic adult soft tissue sarcoma. Sarcoma 1998;2:29-33
   PubMedGoogle Scholar
• Santoro A, Romanini A, Rosso A, et al. Lack of activity of docetaxel in soft tissue sarcomas: results of a phase II study of the Italian group on rare tumors. Sarcoma 1999;3:177-81
   PubMedGoogle Scholar
• Casper ES, Waltzman RJ, Schwartz GK, et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest 1998;16:442-6
   PubMed Web of Science ®Google Scholar
• Patel SR, Linke KA, Burgess MA, et al. Phase II study of paclitaxel in patients with soft tissue sarcomas. Sarcoma 1997;1:95-7
   PubMedGoogle Scholar